分子核医学的发展和应用前景

方圣伟 ,  奚望 ,  张宏

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2009,  33 > 6: (321-326)  
引用本文:
shu
Citation:
shu

分子核医学的发展和应用前景

  • 浙江大学医学院附属第二医院核医学科, 浙江大学氏学PET中心, 浙江大学核医学与分子影像研究所、浙江省医学分子影像重点实验室, 杭州, 310009

The developments and applications of molecular nuclear medicine

  • Department of Nuclear Medwine, Second Affiliated Hospital of Zhejiang University Schoolof Medicine, Zhejiaag University Medical PET Center, Institute of Nuclear Medicine and Molecular Imoging Zhejiang Province, Hangzhou 310009, China

  • 摘要: 分子核医学是分子影像学的重要组成部分,主要包括PET和SPECT技术。目前,CT、MRI、超声、光学成像等影像技术与分子核医学影像技术的融合,以及多模式放射性药物探针的研究及应用成为核医学的主要发展方向。分子核医学在疾病的生物治疗疗效评估研究,基因治疗及其监测,干细胞生长、繁殖、迁移监测,以及新药的开发和筛选等生命科学研究方面将有越来越广泛的应用。
    Abstract: Molecular nuclear medicine including PET and SPECT is one of the most important parts of the molecular imaging.The combinations of molecular unclear medicine with CT,MRI,ultrasound or optical imaging and synthesis of muhimodality radiopharmaceuticals are the major trends of the development of nuclear medicine.Molecular nuclear medicine has more and more important value on the monitoring of response to biology involved gene therapy or stem cell therapy and the developments of new drug.
  • [1] De Wever W,Coolen J,Verschakelen JA.Integrated PET/CT and cancer imaging.JBR-BTR,2009,92(1):13-19.
    [2] Mittra E,Quon A.Positron emission tomography/computed tomography:the current technology and applications.Radiol Clin North Am,2009,47(1):147-160.
    [3] De Wever W,Stroobants S,Verschakelen JA.Integrated PET/CT in lung cancer imaging:history and technical aspects.JBR-BTR,2007,90(2):112-119.
    [4] Pichler BJ,Judenhofer MS,Pfannenberg C.Multimodal imaging approaches:PET/CT and PET/MRI.Handb Exp Pharmacol,2008,185(Pt 1):109-132.
    [5] Shao Y,Cherry SR,Farahani K,et al.Development of a PET detector system compatible with MKI/NMR systems.IEEE Transact Nucl Sci,1997,44(3):1167-1171.
    [6] Pichler BJ,Judenhofer MS,Catana C,et al.Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI.J Nucl Med,2006,47(4):639-647,
    [7] Catana C,Procissi D,Wu Y,et al.Simultaneous in vivo positron emission tomography and magnetic resonance imaging.Proc Natl Acad Sci USA,2008,105(10):3705-3710.
    [8] Antoch G,Bockisch A.Combined PET/MRI:a new dimension in whole-body oncology imaging?.Eur J Nucl Med Mol Imaging,2009,36(Suppl 1):S113-S120.
    [9] Judenhofer MS,Wehrl HF,Newport DF,et al.Simultaneous PET-MRI:a new approach for functional and morphological imaging.Nat Med,2008,14(4):459-465.
    [10] Pichler BJ,Judenhofer MS,Wehrl HF.PET/MRI hybrid imaging:devices and initial results.Eur Radiol,2008,18(6):1077-1086.
    [11] Seemann MD.Whole-body PET/MRI:the future in oncological imaging.Technol Cancer Res Treat,2005,4(5):577-582.
    [12] Tartis MS,Kruse DE,Zheng H,et al.Dynamic micro PET imaging of ultrasound contrast agents and lipid delivery.J Control Release,2008,131(3):160-166.
    [13] Charnley N,Donaldson S,Price P.Imaging angiogenesis.Methods Mol Biol,2009,467:25-51.
    [14] Dijkgraaf I,Beer AJ,Wester HJ.Application of RGD-containing peptides as imaging probes for alphavbeta3 expression.Front Biosci,2009,14:887-899.
    [15] Huber JS,Moses WW,Pouliot N,et al.Dual-modality PET/ultrasound imaging of the prostate.Nuclear Science Symposium Conference Record,2005 IEEE.2005:2187-2190.
    [16] Choy G,Choyke P,Libutti SK.Current advances in molecular imaging:noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research.Mol Imaging,2003,2(4):303-312.
    [17] Dothager RS,Flentie K,Moss B,et al.Advances in bioluminescence imaging of live animal models.Curr Opin Biotechnol,2009,20(1):45-53.
    [18] Waerzeggers Y,Klein M,Miletic H,et al.Multimodal imaging of neural progenitor cell fate in rodents.Mol Imaging,2008,7(2):77-91.
    [19] Zhao H,Gao F,Tanikawa Y,et al.Time-resolved diffuse optical tomography and its application to in vitro and in vivo imaging.J Biomed Opt,2007,12(6):062107.
    [20] Alexandrakis G,Rannou FR,Chatziioannou AF.Effect of optical property estimation accuracy on tomographic bioluminescence imaging:simulation of a combined optical-PET (OPET)system.Phys Med Biol,2006,51(8):2045-2053.
    [21] Prout DL,Silverman RW,Chatziioannou A.Detector concept for OPET-A combined PET and optica imaging system.IEEE Trans Nucl Sci,2004,51(3):752-756.
    [22] Alexandrakis G,Rannou FR,Chatziioannou AF.Tomographic bioluminescence imaging by use of a combined optical-PET(OPET) system:a computer simulation feasibility study.Phys Med Biol,2005,50(17):4225-4241.
    [23] Goetz C,Breton E,Choquet P,et al.SPECT low-field MRI system for small-animal imaging.J Nucl Med,2008,49(1):88-93.
    [24] Rufini V,Shulkin B.The evolution in the use of MIBG in more than 25 years of experimental and clinical applications.Q J Nucl Med Mol Imaging,2008,52(4):341-350.
    [25] Lee HY,Li Z,Chen K,et al.PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles.J Nucl Med,2008,49(8):1371-1379.
    [26] Cai W,Chen K.Li ZB,et al. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.J Nucl Med,2007,48(11):1862-1870.
    [27] Bhushan KR,Misra P,Liu F,et al.Detection of breast cancer microcalcifications using a dual-modality SPECT/NIR fluorescent probe.J Am Chem Soc,2008,130(52):17648-17649.
    [28] Pene F,Courtine E,Cariou A,et al.Toward theragnostics.Crit Care Med,2009,37(1 Suppl):S50-S58.
    [29] Waerzeggers Y,Monfared P,Viel T,et al.Methods to monitor gene therapy with molecular imaging.Methods,2009,48(2):146-160.
    [30] Medarova Z,Pham W,Farrar C,et al.In vivo imaging of siRNA delivery and silencing in tumors.Nat Med,2007,13(3):372-377.
    [31] Miyagawa T,Gogiberidze G,Serganova I,et al.Imaging of HSV-tk reporter gene expression:comparison between[18F]FEAU,[18F]FFEAU,and other imaging probes.J Nucl Med,2008,49(4):637-648.
    [32] Xing L, Deng X,Kotedia K,et al.Non-invasive molecular and functional imaging of cytosine deaminase and uracil phosphoribosyltransferase fused with red fluorescence protein.Acta Oncol,2008,47(7):1211-1220.
    [33] Zhang H,Zheng X,Yang X,et al.11C-NMSP/18F-FDG microPET to monitor neural stem cell transplantation in a rat model of traumatic brain injury.Eur J Nucl Med Mol Imaging,2008,35(9):1699-1708.
    [34] Zinn KR,Chaudhuri TR.The type 2 human somatostatin receptor as a platform for reporter gene imaging.Eur J Nucl Med Mol Imaging,2002,29(3):388-399.
    [35] Wolny M,Syrenicz A.Sodium iodide symporter in physiology and diseases-the current state of knowledge,Endokrynol Pol,2007,58(6):512-521.
    [36] van Dillen IJ,Mulder IVH,Vaalburg W,et al.Influence of the bystander effect on HSV-tk/GCV gene therapy.A review.Curr Gene Ther,2002,2(3):307-322.
    [37] Jacobs A,Tjuvajev JG,Dubrovin M,et al.Positron emission tomography-based imaging of transgene expression mediated by replication-conditional,oncolytic herpes simplex virus type 1mutant vectors in vivo.Cancer Res,2001,61(7):2983-2995.
    [38] 赵春华.干细胞原理、技术与临床应用.北京:化学工业出版社.2006.
    [39] Tjuvajev JG,Stockhammer G,Desai R,et al.Imaging the expression of transfected genes in vivo.Cancer Res,1995,55(24):6126-6132.
    [40] Tjuvajev JG,Avril N,Oku T,et al.Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography.Cancer Res,1998,58(19):4333-4341.
    [41] Yaghoubi SS,Gambhir SS.PET imaging of herpes simplex virus type 1 thymidine kinase(HSV1-tk) or mutant HSV1-sr39tk reporter gene expression in mice and humans using[18F]FHBG.Nat Protoc,2006,1(6):3069-3075.
    [42] Cao F,Lin S,Xie X,et al.In vivo visualization of embryonic stem cell survival,proliferation,and migration after cardiac delivery.Circulation,2006,113(7):1005-1014.
    [43] Willmann JK,van Bruggen N,Dinkelborg LM,et al.Molecular imaging in drug development.Nat Rev Drug Discov,2008,7(7):591-607.
    [44] Dimasi JA.Risks in new drug development:approval success rates for investigational drugs.Clin Pharmacol Ther,2001,69(5):297-307,
    [45] Fischman AJ,Alpert NM,Rubin RH.Pharmacokinetic imaging:a noninvasive method for determining drug distribution and action.Clin Pharmacokinet,2002,41(8):581-602.
    [46] Zhu Z,Guo N,Narendran R,et al.The new PET imaging agent[11C] AFE is a selective serotonin transporter ligand with fast brain uptake kinetics.Nucl Med Biol,2004,31(8):983-994.
    [47] Bergstrom M,Westerberg G,Nemeth G,et al.MAO-A inhibition in brain after dosing with esuprone,moclobemide and placebo in healthy volunteers:in vivo studies with positron emission tomography.Eur J Clin Pharmacol,1997,52(2):121-128.
    [48] Czernin J,Phelps ME.Positron emission tomography scanning:current and future applications.Annu Rev Med,2002,53:89-112.
    [49] Blankenberg FG,Backer MV,Levashova Z,et al.In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HVNIC-VEGF.Eur J Nucl Med Mol Imaging,2006,33(7):841-848.
    [50] Beer AJ,Haubner R,Goebel M,et al.Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.J Nucl Med.2005,46(8):1333-1341.
    [51] Weber WA.Positron emission tomography as an imaging biomarker.J Clin Oncol,2006,24(20):3282-3292.
  • [1] 吕靖 , 张一帆 . 核素分子显像监测胚胎干细胞及诱导性多潜能干细胞移植的研究进展. 国际放射医学核医学杂志, 2014, 38(2): 106-109. doi: 10.3760/cma.j.issn.1673-4114.2014.02.009
    [2] 李天然 , 田嘉禾 . 功能与分子影像学的内涵与范畴. 国际放射医学核医学杂志, 2007, 31(4): 193-196.
    [3] 陈敏 , 魏玲格 , 刘晓梅 . 肿瘤血管生成的分子影像学研究进展. 国际放射医学核医学杂志, 2012, 36(2): 65-68. doi: 10.3760/cma.j.issn.1673-4114.2012.02.001
    [4] 朱羽苑 , 黄钢 . 分子核医学显像展望：多参数分子显像时代. 国际放射医学核医学杂志, 2010, 34(3): 129-134. doi: 10.3760/cma.j.issn.1673-4114.2010.03.001
    [5] 裴之俊 , 张永学 . 报告基因显像监测干细胞治疗的研究进展. 国际放射医学核医学杂志, 2010, 34(2): 73-75, 87. doi: 10.3760/cma.j.issn.1673-4114.2010.02.002
    [6] 张国鹏 , 张永学 . 心肌缺血性疾病基因治疗及分子影像监测进展. 国际放射医学核医学杂志, 2008, 32(5): 257-260.
    [7] 翟红彦 , 苏成海 . 基因治疗联合放射治疗恶性肿瘤的分子机制. 国际放射医学核医学杂志, 2009, 33(2): 113-116. doi: 10.3760/cma.j.issn.1673-4114.2009.02.015
    [8] 王芹 , 刘晓秋 , 李进 , 荣庆林 , 宋力 , 刘强 , 张恒 , 樊飞跃 . 白细胞介素21基因联合不同剂量γ射线照射对乳腺癌细胞生长的影响. 国际放射医学核医学杂志, 2012, 36(2): 94-96. doi: 10.3760/cma.j.issn.1673-4114.2012.02.009
    [9] 王朋 , 兰晓莉 , 张永学 , 齐红艳 . 股骨头缺血性坏死基因治疗及早期影像学监测的研究进展. 国际放射医学核医学杂志, 2012, 36(3): 129-133. doi: 10.3760/cma.j.issn.1673-4114.2012.03.001
    [10] 张锦明 , 田嘉禾 , 刘伯里 . 影响PET放射性药物11C甲基化的因素. 国际放射医学核医学杂志, 2006, 30(5): 271-274.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1967
  • HTML全文浏览量:  442
  • PDF下载量:  7
出版历程
  • 收稿日期:  2009-08-10

分子核医学的发展和应用前景

  • 浙江大学医学院附属第二医院核医学科, 浙江大学氏学PET中心, 浙江大学核医学与分子影像研究所、浙江省医学分子影像重点实验室, 杭州, 310009
  • 收稿日期: 2009-08-10

摘要: 分子核医学是分子影像学的重要组成部分,主要包括PET和SPECT技术。目前,CT、MRI、超声、光学成像等影像技术与分子核医学影像技术的融合,以及多模式放射性药物探针的研究及应用成为核医学的主要发展方向。分子核医学在疾病的生物治疗疗效评估研究,基因治疗及其监测,干细胞生长、繁殖、迁移监测,以及新药的开发和筛选等生命科学研究方面将有越来越广泛的应用。

English Abstract

    全文HTML

参考文献 (51)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net